David Einstein
1.1K posts
David Einstein
@davidjeinstein
Disease Group Leader, GU Medical Oncology @BIDMChealth @DanaFarber_GU, Asst Prof @harvardmed, dad, cyclist, Far Side superfan
#GU26 This is the highest level of data on role of HT. Included 6057 patients with a median follow-up of 9·0 years -Adding HT to RT did not significantly improve OS w/ HR 0.87.
Of the 19 patients with negative PET, 16 interrupted treatment, of whom only 3 resumed to date. Of the 36 patients with previously untreated PSMA avid disease, 11 received RT to residual disease, and 18 interrupted treatment of whom only 6 resumed to date.
#GU26 and #fengsymposium was a blast to see progress. Hoping it eventually moves away from San Fran 😁. Another red eye on the books back home. My observations from PCa sessions: - the field continues to push for over tx and many fail to recognize high risk dz is not high risk anymore for most patients. Enzarad negative, Rtog 0924 neg, ascend-RT neg for MFS/OS, peace2 neg. RT+ADT plenty for most. Many need even less. Select trials paving the way. - for mHSPC not all patients need doublet let alone triplet; age matters - continuous ADT can often be more harmful than helpful now with MDT -most BCR patients post RP do not need ADT—> get biomarker testing to help -many have jumped on bandwagon that OS too hard to improve and settling for early non-surrogate endpoints; peace3 should remind us it’s possible -sequential PARPi /Abi often just as good as combination -early germline/somatic testing for all high risk disease remains without data to support it; even testing in mHSPC unclear benefit as can give PARPi in mCRPC setting (earlier not better than later). -actinium RLT promising but toxicity remains concern -neoadj before RP remains largely ineffective, adds costs and toxicity and most still need postop tx.
#GU26 @TheLancet Extremely proud to co-lead with @AmarUKishan and all investigators in MARCAP for helping make these exciting results possible. Presents POSEIDON assessing use of hormone therapy use and duration with post-op RT for recurrent PCa: An individual patient data meta-analysis of 6 trials thelancet.com/journals/lance… @ASCO
🔜 @asco #GU26 “Our findings demonstrate significantly more #immune cell infiltration in HG vs LG PC, challenging the notion that PC is immunologically “cold”…” #ProstateCancer #Immunotherapy Possible binary designation of 🧊 &🔥 was not best way to look at microenvironment
Don’t miss the latest Uromigos podcast! 🎧 Episode 473 features @davidjeinstein discussing the EMBARK study, high-risk BCR prostate cancer, PSMA PET imaging, and MFS data informing clinical decision-making. Listen now! 🔗GuOncology Now: buff.ly/qoenIu7 🎧Apple Podcasts: buff.ly/oDJkhax 🎧 Spotify: buff.ly/Uwz1GHQ #Uromigos #GUOncology
